SWK Holdings Corp

SWK — Investor Presentation (April 2023)

33 slides from SWK's investor presentation, Apr 4, 2023

  1. Slide 1: Collaborative Approach to Life Science Financing Shareholder Presentation

    1 Collaborative Approach to Life Science Financing Shareholder Presentation April 3, 2023

  2. Slide 2: Forward-looking and Cautionary Statements

    2 Forward - looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we be lieve or anticipate will or may occur in the future are "forward - looking" statements within the meaning of the federal secu

  3. Slide 3: SWK Holdings - Overview

    SWK Holdings - Overview 3 Underserved, High - Need Market Demonstrated Success, Attractive Returns Focus on Shareholder Returns Custom financing solutions for commercial - stage healthcare companies and royalty owners • SWK targets $5mm to $25mm financings, a market niche that is largely ignored by

  4. Slide 4: SWK Holdings - Segments

    4 SWK Holdings - Segments LIFE SCIENCE SPECIALTY FINANCE ENTERIS BIOPHARMA • Senior secured term loans • Royalties • Synthetic royalties • Hybrid structures • Peptelligence ® and ProPerma Œ dosing technologies • CDMO and CMO services • 505b2 drug development SWK operates through two segments: Life S

  5. Slide 5: Life Science Finance Opportunity

    5 Life Science Finance Opportunity Achieve high current yield from investment in non - correlated assets Access to capital is challenging for small/mid - sized life science companies - Few participants exist for sub - $25mm life science financings Life science products are highly portable - Approved

  6. Slide 6: Value Creation Strategy

    6 Value Creation Strategy Deploy balance sheet capital into secured financing portfolio • SWK has established reputation as a go - to capital provider for this underserved market • Majority of financings structured with warrants or other equity - like upside features to enhance return profile Optimi

  7. Slide 7: Book Value Components

    7 Book Value Components Tangible Finance Book Value / Share = $19.02 • Excludes value of deferred tax asset, net Enteris intangibles and goodwill * , and Enteris PP&E • SWK’s targets 10%+ CAGR of tangible finance book value / share Plus: Enteris Biopharma Net Book Value / Share = $0.87 • In 2019, SW

  8. Slide 8: Corporate Milestones

    8 Corporate Milestones 2016 x Team rebuilt and investment process improved x Ended year with $130.0mm investment assets 2017 x Holmdel sold – 3.5x CoC return x Ended year with $154.9mm investment assets 2018 x Secured $20mm credit facility with Cadence Bank (f/k/a State Bank) x Announced share repur

  9. Slide 9: Fourth Quarter 2022 Recap

    Fourth Quarter 2022 Recap 9 CONFIDENTIAL CORPORATE UPDATES FINANCE RECEIVABLES UPDATES • Jody Staggs named President and Chief Executive Officer • Yvette Heinrichson named Chief Financial Officer • Dr. Paul Shields named Chief Executive Officer of Enteris • During the fourth quarter of 2022, closed

  10. Slide 10: Finance Segment Portfolio Overview: 4Q22

    10 Finance Segment Portfolio Overview: 4Q22 * Finance receivables and marketable investments; does not include new or repaid finance receivables closed post - quarter. ** Includes public company warrants; private warrants carried at zero value / not valued on balance sheet • Yielding Assets: * $236.

  11. Slide 11: Financial Snapshot

    11 Financial Snapshot * Eliminates provision for income taxes, Enteris intangibles amortization, and non - cash mark - to - market changes on warrant assets and equity securities; see reconciliation on page 30; 2019 Non - GAAP Adjusted Net Income was reduced by $1.2mm of Enteris transaction expenses

  12. Slide 12: Financing Strategy: Effective Yields

    12 Financing Strategy SWK Targets Low - to - Mid Teens Effective Yields 4Q22 Finance Segment Effective Yield was 13.9% * Effective yield is the rate at which income is expected to be recognized pursuant to the Company’s revenue recognition poli cie s, if all payments are received pursuant to the ter

  13. Slide 13: Financing Strategy: Realized Yield vs Projected

    13 Financing Strategy SWK’s Portfolio Realized Yield Has Consistently Exceeded the Projected Yield as Actual Receipts Exceeded Internal Forecasts *Portfolio Realized Yield is inclusive of all fees and is calculated based on the simple average of finance receivables at th e b eginning and end of peri

  14. Slide 14: Current Structured Credit Portfolio

    14 Current Structured Credit Portfolio Trio Healthcare 07.01.2021 $9.5 million Structured Credit Advanced Oxygen Therapy 03.21.2022 $12.0 million Structured Credit Aziyo Biologics 08.10.2022 $25.0 million Structured Credit BIOLASE 11.09.2018 $15.0 million Structured Credit Biotricity 12.27.2021 $12.

  15. Slide 15: Current Royalty Portfolio

    15 Current Royalty Portfolio Best ABT 11.12.2018 $5.8 million Royalty Reorganization Cambia 07.31.2014 $9.5 million Royalty Acquisition ForFivo ( IntelGenx ) 08.05.2016 $6.0 million Royalty Acquisition Illuvien 12.18.2020 $16.5 million Royalty Acquisition Women’s Health 06.07.2013 $3.0 million Royal

  16. Slide 16: Portfolio Realizations

    16 Portfolio Realizations $ in 000s # Investments Security Origination Payoff Cash Invested Cash Received MOIC XIRR Exit Form Factor 1 Nautilus Loan 12/05/12 12/17/13 22,500$ 28,606$ 1.3x 28%Acquired by Strategic 2 Parnell I Loan 01/23/14 06/27/14 25,000$ 27,110$ 1.1x 21% Refinanced 3 Response Genet

  17. Slide 17: Portfolio Realizations to Strategic Buyers

    17 Portfolio Realizations to Strategic Buyers 13 realizations to strategic buyers demonstrated a median 28% LTV of SWK’s original loan value 9 of the 13 businesses were not profitable at time of sale, validating SWK’s revenue and IP - based underwriting methodology $ in mm Target Buyer Closing Date

  18. Slide 18: Sourcing

    18 Sourcing • SWK has a well - developed and diversified sourcing network • SWK balances proprietary opportunities with deal flow from trusted, boutique investment banks and brokers • SWK typically faces limited competition due to proprietary sourcing network and focus on sub - $25mm financings • Fr

  19. Slide 19: Financing Structures

    Financing Structures 19 Product Acquisition • Primarily first lien senior secured loans, though will selectively evaluate second lien opportunities • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support product commer

  20. Slide 20: Value Proposition to Partners

    20 Value Proposition to Partners Smaller companies often don’t have financial profile to qualify for traditional financing sources Companies in this niche often have few options outside of a dilutive equity raise The IPO market is largely closed to companies of this size requiring expensive and diff

  21. Slide 21: Historical Financing: Narcan Royalty

    Historical Financing: Narcan Royalty 21 OPPORTUNITY SOLUTION • Opiant is a publicly - traded drug development company that receives a royalty on Narcan for developing the drug’s unique formulation • Novel formulation has a faster time to onset and more convenient and safer administration • Opiant ne

  22. Slide 22: Historical Financing: Galil Medical

    Historical Financing: Galil Medical 22 OPPORTUNITY SOLUTION • In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cash - flow positive and could not tap traditional financing channels • Galil needed additional capital to run clinical trials and expand its sales force • In

  23. Slide 23: Enteris Corporate Overview

    23 Enteris Corporate Overview CDMO Platform Proven Technology, Late - Stage Commercial Partnerships, and Internal Pipeline Drug Delivery Technology Internal 505(b)(2) Pipeline Company Highlights • Peptelligence and ProPerma allow for oral delivery of drugs that are typically injected, including pept

  24. Slide 24: Enteris: Cara Therapeutics and Oral KORSUVA

    Enteris: Cara Therapeutics and Oral KORSUVA Œ 24 Oral KORSUVA Licensing Agreement Milestone Payment • Formulated with Enteris ’ Peptelligence technology • Currently the subject of three late - stage clinical trials for pruritus: • Phase 3 trial targeting pruritus associated with non - dialysis depen

  25. Slide 25: Leadership Team

    25 Leadership Team Yvette Heinrichson Chief Financial Officer • Joined in 2016 • Technical GAAP accounting and SEC financial reporting • Certified Fraud Examiner • Served as financial statement auditor and tax professional with Deloitte for multiple years Jody Staggs President and Interim CEO • Join

  26. Slide 26: Why Invest in SWKH - Attractive Risk Reward Scenario

    Why Invest in SWKH – Attractive Risk Reward Scenario 26 Unleveraged Balance Sheet and Buyback • SWK story is not widely known, having uplisted to Nasdaq without benefit of traditional IPO • Analyst coverage and proactive investor relations effort have helped to increase SWK’s visibility • With a Boo

  27. Slide 27: Balance Sheet

    27 Balance Sheet Certain asset and liabilities were classified as “current” in prior years; thus, prior periods may not be directly comparable . $ in 000s Dec-22 Dec-21 Dec-20 Dec-19 Dec-18 ASSETS Cash and cash equivalents 6,156$ 42,863$ 3,008$ 11,158$ 20,227$ Interest and accounts receivable,net 3,

  28. Slide 28: Income Statement

    28 Income Statement $ in 000s, except per share amounts Dec-22 Dec-21 Dec-20 Dec-19 Dec-18 Revenues Finance receivable interest income, including fees 35,461$ 39,310$ 30,800$ 30,117$ 25,978$ Pharmaceutical development 5,485 16,122 5,903 621 - Other 538 723 9 9 12 Total revenues 41,484 56,155 36,712

  29. Slide 29: Cash Flow Statement

    29 Cash Flow Statement $ in 000s Dec-22 Dec-21 Dec-20 Dec-19 Dec-18 Cash flows from operating activities Net income 13,491$ 25,929$ 5,202$ 23,828$ 6,195$ Adjustments to reconcile net income to net cash provided by operating activities Provision for loan credit losses 3,491 - - 2,209 6,179 Impairment

  30. Slide 30: Reconciliation of Non-GAAP Adjusted Net Income

    30 Reconciliation of Non - GAAP Adjusted Net Income The following tables provide a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated ne t income (Non - GAAP) for the periods denoted in the table. The table eliminates provisions for income taxes, non - cas

  31. Slide 31: Reconciliation of Non-GAAP Specialty Finance Net Income

    31 Reconciliation of Non - GAAP Specialty Finance Net Income The following tables provide a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non - GAAP adjusted net income for the specialty finance business for the periods deno

  32. Slide 32: Contact Information

    32 Contact Information CONFIDENTIAL SWK Senior Management Investor & Media Relations: Tiberend Strategic Advisor • Jody Staggs: ̶ Phone: 972.687.7252 ̶ Email: [email protected] • Office address: ̶ 14755 Preston Road, Ste 105 Dallas, TX 75254 • Website: www.swkhold.com • Jason Rando: ̶ Email: jrand

  33. Slide 33: Collaborative Approach to Life Science Financing

    33 Collaborative Approach to Life Science Financing

SWK Holdings — Investor Presentation (April 2023) on 6ix